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ABSTRACT
Farnesoid X receptor (FXR, NR1H4) is a member of the nuclear receptor 
superfamily of ligand-activated transcription factors. Since the role of FXR in osteoclast 
differentiation remains ill-defined, we investigated the biological function of FXR on 
osteoclastogenesis, using FXR-deficient mice. We demonstrated that FXR deficiency 
increases osteoclast formation in vitro and in vivo. First, FXR deficiency was found to 
accelerate osteoclast formation via down-regulation of c-Jun N-terminal kinase (JNK) 
1/2 expression. Increased expression of peroxisome proliferator-activated receptor 
(PPAR)γ and peroxisome proliferator-activated receptor gamma coactivator 1 (PGC-
1)β seems to mediate the pro-osteoclastogenic effect of FXR deficiency via the JNK 
pathway. In addition, we found that FXR deficiency downregulated the expression of 
interferon-β (IFN-β), a strong inhibitor of osteoclastogenesis, via receptor activator 
of nuclear factor-kappaB ligand (RANKL). We further suggested that interference of 
IFN-β expression by FXR deficiency impaired the downstream JAK3-STAT1 signaling 
pathways, which in turn increased osteoclast formation. Finally, FXR deficiency 
accelerated unloading- or ovariectomy-induced bone loss in vivo. Thus, our findings 
demonstrate that FXR is a negative modulator in osteoclast differentiation and identify 
FXR as a potential therapeutic target for postmenopausal osteoporosis and unloading-
induced bone loss.
INTRODUCTION
Bone is consistently renewed throughout life by 
the opposing activities of osteoblastic bone formation 
and osteoclastic bone resorption pathways. Although 
osteoclasts are required for bone remodeling, excess 
activity of osteoclasts can lead to various diseases 
such as periodontal disease, osteoporosis, rheumatoid 
arthritis, multiple myeloma, and metastatic cancers [1–3]. 
Osteoclasts are giant multinucleated cells derived from 
hematopoietic precursors of the monocyte-macrophage 
lineage. During osteoclastogenesis, bone marrow-derived 
macrophages (BMMs) differentiate into tartrate-resistant 
acid phosphatase (TRAP)-positive pre-osteoclasts, which 
then fuse with each other to form mature osteoclasts [4–6].
Macrophage colony-stimulating factor (M-CSF) 
and receptor activator of nuclear factor kappa-B ligand 
(RANKL) provide the two necessary and sufficient 
signals for osteoclast differentiation. Binding of M-CSF 
to its receptor, CSF-1R, in osteoclast precursors promotes 
their proliferation and survival via the activation of 
kinases such as Src, phospholipase C-gamma (PLC-γ), 
phosphoinositide 3-kinase (PI3K), protein kinase B (PKB, 
also AKT) and extracellular signal-regulated kinase 1/2 
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(ERK1/2) [7–9]. RANKL binding to RANK induces the 
association of RANK with tumor necrosis factor receptor-
associated factor 6 (TRAF6), which activates nuclear 
factor-kappaB (NF-κB) and mitogen-activated protein 
kinases (MAPKs; ERK1/2, p38, and stress-activated 
protein kinase/c-Jun N-terminal kinase (SAPK/JNK)). In 
turn, these kinases activate nuclear factor of activated T 
cells (NFATc1), the master transcription factor responsible 
for osteoclast differentiation and function [10].
The farnesoid X receptor (FXR, NR1H4) is 
a member of the nuclear receptor superfamily of 
transcription factors that regulates multiple biological 
processes. Bile acid has been identified as endogenous 
ligands for FXR [11–13]. Upon ligand-induced activation, 
FXR binds to FXR response elements [14] either as a 
monomer or as a heterodimer with the retinoid X receptor 
(RXR) [13, 14] and modulates bile acids, lipid and glucose 
metabolism, inflammation, and energy metabolism 
[11, 12]. Given all of these benefits, FXR has been 
considered as a therapeutic target for the treatment of 
metabolic disorders [19, 20].
Several studies suggest that FXR has complex 
roles in the pathogenesis of metabolic dysfunction, 
and its activity in different tissues could possibly exert 
different effects on metabolism [11–20]. We previously 
demonstrated that the deletion of FXR (FXR−/−) in vivo 
resulted in a significant reduction in bone mineral density 
compared with that in FXR+/+ mice [21]. Since the 
mechanism by which FXR modulates bone metabolism 
has not been fully explored, we investigated a specific 
role of FXR in the modulation of osteoclastogenesis and 
bone loss in vitro and in vivo. Our work demonstrates that 
FXR could be exploited to prevent the development of 
osteoclast-associated bone diseases. 
RESULTS
FXR deficiency facilitates osteoclast 
differentiation
To explore the functional role of FXR in osteoclast 
differentiation, we first examined the endogenous 
expression of FXR in BMMs by RANKL. The mRNA 
and protein expression levels of FXR were significantly 
decreased in BMMs by RANKL treatment (Figure 1A, 
1B). Thus, we investigated the role of FXR on RANKL-
induced osteoclast formation, using an activator and an 
inhibitor of FXR. Activation of FXR by chenodeoxycholic 
acid (CDCA) decreased the formation of TRAP+ 
multinucleated cells (MNCs), whereas inhibition of 
FXR by guggulsterone significantly enhanced the 
formation of TRAP+ MNCs by RANKL (Figure 1C). We 
next overexpressed FXR in BMMs, using a retrovirus 
(Supplementary Figure 1). Overexpression of FXR in 
BMMs significantly inhibited the formation of TRAP+ 
MNCs mediated by RANKL when compared with that in 
the control vector (Figure 1D). In accordance with these 
results, overexpression of FXR attenuated the RANKL-
induced expression of NFATc1 during RANKL-mediated 
osteoclastogenesis (Figure 1E). Taken together, these 
data suggested that FXR has a negative role in RANKL-
mediated osteoclast differentiation.
To further investigate the role of FXR on osteoclast 
formation in vivo, we conducted histomorphometric 
analyses of bone sections from the distal femur of FXR+/+ 
and FXR−/− mice. FXR deficiency increased the number 
of osteoclasts per bone surface (N.Oc/BS; Figure 1F). 
Both the number of TRAP+ mononuclear cells (N.Mo.
TRAP+ cells/BS) and multinuclear osteoclasts (N.Mu.
Oc/BS) per bone surface were increased in FXR−/− 
compared with FXR+/+ femur (Figure 1G and 1H). FXR 
deficiency also enhanced the levels of osteoclast surface 
per bone surface (Oc.S/BS; Figure 1I). These observations 
indicate that FXR deficiency increases osteoclastogenesis 
in vivo. Furthermore, the role of FXR in the context of 
inflammation-induced osteoclastogenesis was examined 
using the lipopolysaccharide (LPS)-challenged bone loss 
model. LPS stimulates osteoclast formation in vivo. When 
LPS was injected into the supra calvaria region of mice, 
the number of TRAP stained-osteoclasts was markedly 
increased in the calvaria of FXR−/− compared with that 
of FXR+/+ mice (Figure 1J, 1K). Collectively, these 
results suggest that FXR is a crucial negative regulator of 
osteoclast differentiation. 
FXR deficiency accelerates osteoclast formation 
via downregulation of JNK 1/2 expression
To clarify the mechanism of increased 
osteoclastogenesis by FXR deletion, we performed in 
vitro experiments, using BMMs isolated from FXR−/− and 
FXR+/+ mice. We first showed that FXR−/− BMMs exhibited 
more TRAP+ MNCs by RANKL in a dose-dependent 
manner, in comparison to FXR+/+ BMMs (Figure 2A). In 
addition, when cultured on dentine slices with RANKL, 
FXR−/− BMMs generated more resorption pits than 
FXR+/+ BMMs, with larger overall area (Figure 2B). 
To examine the mechanisms underlying the 
osteoclastogenic increase in FXR−/− BMMs, we 
investigated the expression of NFATc1, a key regulator of 
osteoclast differentiation. There was a higher increase in 
the expression level of NFATc1 by RANKL in FXR−/− 
BMMs than in FXR+/+ BMMs (Figure 2C). Next, we 
investigated the role of FXR in the regulation of RANKL-
dependent signaling pathways, including ERK, p38, 
JNK1/2, NF-κB, and AKT. There was no significant 
difference in ERK, p38, NF-κB, and AKT activation by 
RANKL between FXR+/+ and FXR−/− BMMs (data not 
shown). In contrast, JNK1/2 phosphorylation by RANKL 
was suppressed in FXR−/− BMMs with a substantial 
change in protein expression (Figure 2D). The reduction 
of JNK1/2 protein expression in FXR−/− BMMs was 
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due to decreased JNK1/2 mRNA levels (Figure 2E). 
Modulation of JNK1/2 expression levels was further 
confirmed by pharmacological activation (CDCA) or 
inhibition (guggulsterone) of FXR (Figure 2F), and 
by overexpression of FXR (Supplementary Figure 2). 
Paradoxically, JNK is known to be critical for RANKL-
Figure 1: FXR negatively regulates osteoclast formation. (A) BMMs from 12-week-old mice were cultured with RANKL (100 
ng/ml) and M-CSF (30 ng/ml) for 4 days. The mRNA levels of FXR were analyzed by real-time PCR. (B) BMMs from 12-week-old mice 
were cultured with RANKL (100 ng/ml) for the indicated times and FXR expression levels were analyzed by western blot. (C) BMMs 
were cultured with RANKL (100 ng/ml) and M-CSF (30 ng/ml) in the presence of 75 μM CDCA or 0.3 μM guggulsterone for 4 days. 
TRAP+ MNCs were counted as osteoclasts when more than 3 nuclei were present. Scale bar, 200 μm. (D) BMMs were infected by mock or 
FXR through a retrovirus packaging system. Infected BMMs were cultured with RANKL (100 ng/ml) and M-CSF (30 ng/ml) for 4 days. 
Scale bar, 200 μm. (E) Infected BMMs were cultured with M-CSF (30 ng/ml) in the presence or absence of RANKL (200 ng/ml) for 48 
h. Cell lysates were then subjected to western blot analysis with anti-NFATc1 antibody. (F–I) Histological bone sections from distal femur 
of FXR+/+ and FXR−/−mice were analyzed. N.Oc./BS (F), N.Mo. TRAP+ cells/BS (G), N.Mu.Oc/BS (H) and Oc.S/BS (I). n = 6 for each 
group. (J–K) Calvarias of FXR+/+ and FXR−/− mice that received the vehicle or LPS were subjected to TRAP staining. TRAP+ stained area 
in calvaria was quantified using ImageJ. Representative images are shown in (K). n = 5 for each group. Scale bar, 500 μm. *p < 0.05, **p 
< 0.01. N.Oc./BS: osteoclast number/bone surface; N.Mo.TRAP+ cells/BS: number of TRAP+ mononuclear cells/bone surface; N.Mu.Oc/
BS: number of multinuclear osteoclast/bone surface; Oc.S/BS: osteoclast surface/bone surface.
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stimulated NFATc1 induction and osteoclast formation 
[2–4]. Thus, we investigated whether pharmacological 
JNK inhibition by SP600125 or down-regulation of JNK 
by siRNA would closely mimic the genetic deletion of 
FXR. Since the basal level of JNK1/2 phosphorylation 
was maintained in FXR−/− BMMs by RANKL (Figure 2D), 
we used a lower concentration (0.3 μM) of SP600125 than 
is normally used (1–10 μM). Interestingly, a low level of 
JNK1/2 inhibition led to a strong increase in osteoclastic 
differentiation by RANKL accompanied by a significant 
induction of NFATc1 (Figure 2G, 2H). Similar effects 
were seen by the use of siRNAs. The introduction of 
JNK-specific siRNA into FXR+/+ BMMs showed a similar 
reduction in JNK1/2 mRNA expression similar to that in 
FXR−/− BMMs (Supplementary Figure 3). Compared to 
that with the control siRNA, the knock-down of JNK1/2 
resulted in a significant increase in NFATc1 expression 
as well as in the formation of TRAP+ MNCs by RANKL 
(Figure 2I, 2J). These results indicate that FXR has a 
negative role in osteoclast differentiation by modulating 
JNK signals downstream to RANKL.
FXR deficiency up-regulates PPARγ and PGC-
1β expression via the JNK pathway
 To gain insight into how FXR modulates osteoclast 
formation via JNK, we investigated the expression of 
genes known to have a role in osteoclastogenesis. We 
found that JNK inhibitor (0.3 μM) or JNK-specific 
siRNA enhanced the mRNA expression of peroxisome 
proliferator-activated receptor (PPAR)γ and peroxisome 
proliferator-activated receptor-gamma coactivator 1 (PGC-
1) β in BMMs (Figure 3A, 3B). Furthermore, activation of 
FXR by CDCA decreased the mRNA expression of PPARγ 
and PGC-1β, whereas inhibition of FXR by guggulsterone 
conversely resulted in an increase in these mRNA 
expressions (Figure 3C). Real-time PCR demonstrated 
that the mRNA expression of PPARγ and PGC-1β was 
significantly increased in FXR−/− BMMs compared with 
that in FXR+/+ BMMs, which is consistent with these 
results (Figure 3D, 3E). Moreover, RANKL-induced 
mRNA expression levels of PPARγ and PGC-1β were 
maintained at significantly higher levels in FXR−/− BMMs 
(Figure 3D, 3E). Similarly, the up-regulation of PPARγ 
protein expression in FXR−/− BMMs was confirmed by 
western blot (Figure 3F). 
PPARγ is a member of the nuclear hormone receptor 
superfamily of ligand-responsive transcription factors that 
can be activated by lipophilic ligands. PPARγ activation 
by rosiglitazone promotes hematopoietic stem cell (HSC) 
differentiation into osteoclasts, thus increasing bone 
resorption [24, 25]. PGC-1β is a transcriptional coactivator 
that regulates energy metabolism by stimulating 
mitochondrial biogenesis and respiration of cells [26–29]. 
PGC-1β is required for the pro-osteoclastogenic and bone 
resorption-enhancing effects of PPARγ [24]. 
Since FXR−/− BMMs have higher expression levels 
of PPARγ and PGC-1β compared to FXR+/+ BMMs, we 
investigated the effect of rosiglitazone, a PPARγ agonist, 
on RANKL-induced osteoclast differentiation from BMM 
cells. As previously reported [30], rosiglitazone increased 
osteoclast formation from FXR+/+ BMMs, and this 
induction was accelerated in FXR−/− BMMs (Figure 3G). 
We also revealed that the level of NFATc1 was increased 
by rosiglitazone in FXR+/+ cells, but was significantly 
higher in FXR−/− cells (Figure 3H). These data suggest 
that up-regulation of PPARγ and PGC-1β expression by 
suppression of the JNK pathway leads to the increased 
osteoclast formation in FXR−/− BMMs.
FXR deficiency accelerates rosiglitazone-induced 
bone loss in vivo
 To further delineate the effect of increased 
PPARγ and PGC-1β expression in FXR−/− BMMs 
on bone resorption and bone loss in vivo, we orally 
administrated FXR+/+ or FXR−/− mice with rosiglitazone 
or vehicle at 10 mg/kg/d for 8 weeks. Femurs from the 
rosiglitazone group became darker in FXR−/− mice than 
in FXR+/+ mice (Figure 4A). The DXA analysis indicated 
that rosiglitazone-mediated reduction in BMD was 
significantly accelerated in the femurs of FXR−/− mice 
(Figure 4B). A micro-CT analysis of the metaphyseal 
region of the femur showed that the trabecular bone 
volume per tissue volume (BV/TV) was significantly 
lower in FXR−/− than FXR+/+ mice following rosiglitazone 
treatment (Figure 4C). Consistently, two other bone 
parameters related to BV/TV – trabecular thickness 
(Tb.Th) and trabecular number (Tb.N; linear density of 
trabecular bone) – were more significantly reduced in 
FXR−/− mice compared with FXR+/+ mice by rosiglitazone 
treatment (Figure 4D, 4E). No obvious difference was seen 
in trabecular separation (Tb.Sp) between rosiglitazone-
treated FXR+/+ and FXR−/− mice (Figure 4F). Rosiglitazone 
treatment also resulted in a high structure model index 
(SMI) in FXR+/+ mice, an indicator of increased fragility, 
which was more significantly increased in FXR−/− mice 
(Figure 4G). Finally, two-dimensional visualization of 
the femoral area clearly showed that the massive loss of 
trabecular bone following rosiglitazone treatment was 
much higher in FXR−/− mice compared with FXR+/+ mice 
(Figure 4H). These results indicate that FXR deficiency 
confers sensitivity to rosiglitazone-induced bone 
resorption and bone loss in vivo.
FXR deficiency accelerates osteoclast formation 
via downregulation of IFN-β signaling pathways
 To balance out osteoclastogenesis, RANKL also 
induces the IFN-β gene in BMMs, and this induction 
constitutes a critical aspect of the negative feedback 
regulation of RANKL signaling that allows for the 
Oncotarget76562www.impactjournals.com/oncotarget
Figure 2: FXR deficiency increases osteoclast differentiation via downregulation of JNK1/2 expression. (A) BMMs from 
FXR+/+ and FXR−/− mice were cultured with M-CSF and the indicated concentration of RANKL for 4 days, and TRAP+ osteoclasts were 
counted. (B) BMMs from FXR+/+ and FXR−/− mice were placed on dentine slices and cultured in the presence of RANKL (100 ng/ml) for 6 
days. The remaining cells were removed and stained with toluidine blue. The images were observed under the microscope. The number of 
resorbed pits was counted and pit area in each dentine was quantified using ImageJ. (C) BMMs from FXR+/+ and FXR−/− mice were cultured 
with RANKL (200 ng/ml) for the indicated time. (D) BMMs from FXR+/+ and FXR−/− mice were serum-starved for 16 h and stimulated 
with RANKL (200 ng/ml) for the indicated time. Cell lysates were then subjected to western blot analysis with anti-NFATc1, anti-p-JNK, or 
anti-JNK antibody. (E) The mRNA expression of JNK1 and JNK2 in FXR+/+ and FXR−/− BMMs was analyzed by real-time PCR. (F) FXR+/+ 
BMMs were cultured in the presence of 75 μM CDCA or 0.3 μM guggulsterone for 48 h. The mRNA expression of JNK1 and JNK2 was 
analyzed by real-time PCR. (G) FXR+/+ BMMs were cultured with RANKL (100 ng/ml) in the presence or absence of SP600125 (0.3 μM), 
a JNK inhibitor, for 4 days. (H) FXR+/+ BMMs were cultured with RANKL (200 ng/ml) in the presence or absence of SP600125 (0.3 μM) 
for 48 h. Cell lysates were then subjected to western blot analysis with anti-NFATc1 antibody. (I) FXR+/+ BMMs were transfected with 40 
nM siRNA. The siRNA-transfected FXR+/+ BMMs were cultured with RANKL (200 ng/ml) for 3 days, and then TRAP+ osteoclasts were 
counted. (J) The siRNA-transfected FXR+/+ BMMs were cultured with RANKL (200 ng/ml) for 48 h. Cell lysates were then subjected to 
western blot analysis with anti-NFATc1 antibody. Data are expressed as means ± SD from at least three independent experiments. Scale 
bar, 200 μm. *p < 0.05.
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Figure 3: FXR deficiency up-regulates PPARγ and PGC-1β expression via downregulation of JNK. (A) FXR+/+ BMMs 
were cultured in the presence or absence of SP600125 (0.3 μM) for 24 h. The mRNA expression of PPARγ or PGC-1β was analyzed by real-
time PCR. (B) FXR+/+ BMMs were transfected with 40 nM siRNA. The mRNA expression was analyzed by real-time PCR using PPARγ 
or PGC-1β primer. (C) FXR+/+ BMMs were cultured with CDCA (75 μM) or guggulsterone (0.3 μM) for 24 h. The mRNA expression of 
PPARγ or PGC-1β was analyzed by real-time PCR. (D–E) BMMs from FXR+/+ and FXR−/− mice were cultured with RANKL (200 ng/ml) 
for the indicated time. The mRNA level was analyzed by real-time PCR with PPARγ (D) or PGC-1β (E) primer. (F) FXR+/+ and FXR−/− 
BMMs were cultured with RANKL (200 ng/ml) for the indicated time. Cell lysates were then subjected to western blot analysis with 
anti-PPARγ antibody. (G) FXR+/+ and FXR−/− BMMs were cultured with RANKL (100 ng/ml) in the presence or absence of rosiglitazone 
(0.3 μM) for 3 days. Scale bar, 200 μm. (H) BMMs from FXR+/+ and FXR−/− mice were cultured with RANKL (200 ng/ml) in presence or 
absence of rosiglitazone (0.3 μM) for 48 h. Cell lysates were then subjected to western blot analysis with anti-NFATc1 antibody. Data are 
expressed as means ± SD from at least three independent experiments. *p < 0.05, **p < 0.01.
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suppression of excessive osteoclastogenesis [31]. 
Since FXR deficiency was shown to increase the 
pro-osteoclastogenic signals from RANKL, we next 
investigated whether FXR deficiency modulates the 
anti-osteoclastogenic mechanism of RANKL. RANKL 
increased mRNA expression of IFN-β in FXR+/+ BMMs, 
and this induction was significantly decreased in FXR−/− 
BMMs (Figure 5A). The phosphorylation of STAT1 is 
known to be essential for IFN-β signaling by RANKL 
[31]. The level of p-STAT1 by RANKL was increased 
in FXR+/+ BMMs, which was completely abrogated in 
FXR−/− BMMs (Figure 5B). In accord with these findings, 
Figure 4: FXR deficiency increases rosiglitazone-induced bone loss in vivo. Male 12-week-old FXR+/+ and FXR−/− mice were 
orally administered daily with rosiglitazone (10 mg/kg) for 2 months, and mouse femurs were collected. (A) Femurs of FXR+/+ or FXR−/− 
mice from each group. (B) BMD (g/cm2) of femurs from FXR+/+ and FXR−/− mice was analyzed by DXA. (C–G) Various bone parameters 
were analyzed by micro-CT. BV/TV (%) (C), Tb.Th (mm) (D), Tb.N (/mm) (E), Tb.Sp (mm) (F), SMI (G). (H) Two-dimensional micro-CT 
images of the distal metaphysis of the femurs. *p < 0.05, **p < 0.01. BMD, bone mineral density; BV/TV, bone volume per tissue volume; 
Tb.Th, trabecular thickness; Tb.N, trabecular number; Tb.Sp, trabecular separation; SMI, structural model index.
Oncotarget76565www.impactjournals.com/oncotarget
overexpression of FXR in BMMs increased the level of 
IFN-β and p-STAT1 by RANKL when compared with the 
results with control vector (Figure 5C, 5D). The STAT 
family is located downstream of the JAKs [30]. We further 
demonstrated that RANKL increases JAK3 mRNA and 
protein levels in FXR+/+ BMMs, but not in FXR−/− BMMs 
(Figure 5E, 5F).
Since the role of JAK3 in osteoclast formation has 
not been determined [32], we next assessed the effect of 
JAK3 downregulation on osteoclast differentiation. We 
found that a pharmacological JAK3 inhibitor accelerates 
RANKL-induced osteoclastogenesis in a dose-dependent 
manner (Figure 5G). Similar effects were seen in BMMs 
transfected with JAK3-specific siRNA (Figure 5H). In 
addition, compared with the control, knock-down of JAK3 
in BMMs resulted in a significant decrease in the level 
of p-STAT1 (Figure 5I), followed by increased NFATc1 
expression by RANKL (Figure 5J). These data suggest 
that the impairment of IFN-β pathways via JAK3-STAT1 
is another mechanism underlying the increased osteoclast 
formation in FXR−/− BMMs. 
FXR deficiency accelerates unloading- or OVX-
induced bone loss in vivo
We showed that FXR has an important role in OC 
differentiation and bone remodeling under physiological 
conditions. Next we used an unloading- or OVX-induced 
bone loss model in order to determine whether deletion of 
FXR affects bone loss under pathological conditions. 
The effect of unloading was first investigated in 
FXR-deficient mice, using tail suspension as a model of 
hindlimb unloading [33]. FXR+/+ and FXR−/− mice were 
subjected to tail suspension at age 8 weeks, and their 
skeletal response was analyzed 1 week later. Unloading 
induced a significantly greater femoral bone loss in FXR–/– 
mice than in FXR+/+ mice (Figure 6A). In agreement, BMD 
was significantly lower in FXR–/– mice than in FXR+/+ mice 
after hindlimb unloading (Figure 6B). As FXR deficiency 
accelerates the unloading-induced reduction in BMD 
levels, we next examined the effects FXR deficiency on 
the microstructural bone deterioration that is induced by 
hindlimb unloading. Three dimensional micro-CT analyses 
revealed that the level of BV/TV in the metaphyseal 
region of the femur was reduced by hindlimb unloading in 
FXR+/+ mice, and FXR deficiency significantly increased 
the unloading-induced reduction in BV/TV (Figure 6C). 
Other bone parameters, including Tb.Th, Tb.N, Tb,Sp, 
and SMI, also confirmed more severe bone loss by 
hindlimb unloading in FXR−/− mice compared to FXR+/+ 
mice (Figure 6D–6G). Furthermore, osteoclastogenesis 
was increased in bone marrow (Figure 6H) or BMM 
cells (Figure 6I) from FXR-/- mice, in comparison to 
those from FXR+/+ mice after tail-suspension. These data 
demonstrated that FXR deficiency accelerates unloading-
induced bone loss in vivo. 
To further investigate the role of FXR in estrogen 
withdrawal-induced bone loss, we examined FXR+/+ and 
FXR–/– mice that were subjected to sham or OVX in vivo. 
Ten weeks after OVX, bone loss was even more severe 
in FXR–/– mice than in FXR+/+ mice (Figure 7A). FXR–/– 
mice showed lower BMD than FXR+/+ mice (Figure 7B). 
In addition, OVX-induced structural bone alterations, 
including decreases in BV/TV, Tb.Th, Tb.N, and SMI, 
were heightened by lack of FXR (Figure 7C–7F). No 
significant difference was seen in Tb.Sp between FXR+/+ 
and FXR−/− mice after OVX (Figure 7G). These data 
demonstrated that FXR deficiency strengthened the OVX-
induced bone loss in vivo. Taken together, out data suggest 
that FXR could be a pivotal modulator of bone loss in vivo 
under pathological conditions.
DISCUSSION
In this study, we suggest a novel role of FXR, a 
bile acid-sensing member of the nuclear receptor family, 
as a negative regulator of RANKL-induced osteoclast 
differentiation. We found that RANKL down-regulates 
FXR expression during osteoclast differentiation. 
Overexpression of FXR in BMMs attenuates RANKL-
induced osteoclast differentiation by down-regulation 
of NFATc1, which is a key modulator for osteoclast 
differentiation. In agreement with this, FXR−/− mice 
exhibited a significantly increased number of osteoclasts, 
which was partly attributed to a severe osteoporotic 
phenotype. In an attempt to elucidate the mechanisms 
by which FXR deficiency increases the osteoclastic 
differentiation, we demonstrated that the phosphorylation 
of JNK1/2 by RANKL as well as the expression of JNK1/2 
were decreased in FXR−/− BMMs. We found that the down-
regulation of JNK activity increased the expression of 
PPARγ and PGC-1β, which might accelerate osteoclast 
formation in FXR−/− BMMs.
The JNKs are members of the MAPK family 
and are activated by environmental stress [34]. The 
mammalian JNKs are encoded by three distinct genes 
(Jnk1, Jnk2, and Jnk3). JNK1 and JNK2 isoforms 
are ubiquitously expressed, whereas JNK3 is almost 
exclusively found in the brain, heart and testis [34]. 
Many previous studies have reported the role of JNK1/2 
in osteoclast formation. In mouse BMMs, JNK activity 
is required during osteoclastogenesis to maintain the 
status of osteoclastic commitment [35]. A study using 
JNK1−/− mice has also reported that activation of JNK1 
is required for the efficient osteoclastogenesis of BMMs 
[36]. However, the present study is distinct from previous 
genetic and pharmacological studies that investigated the 
effects of a complete JNK blockade. In the present study, 
although FXR deficiency failed to effectively induce 
JNK phosphorylation by RANKL, the basal level of 
JNK phosphorylation was still maintained in BMMs. We 
speculate that the maintenance JNK phosphorylation at a 
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basal level permits the acceleration of osteoclastogenesis 
by increased PPARγ-PGC-1β expression. 
There is much evidence to show that the nuclear 
receptor PPARγ regulates skeletal homeostasis through its 
direct effect on osteoclasts [25, 30, 37, 38]. Genetically, the 
loss of PPARγ function in mouse hematopoietic lineages 
causes osteoclast defects, which present as osteopetrosis [25]. 
Pharmacologically, rosiglitazone-induced PPARγ activation 
causes bone loss in mice by enhancing osteoclastogenesis 
and bone resorption in vivo [25]. PPARγ modulates 
transcription through the ligand-mediated recruitment of 
coactivators [39]. PGC-1β (also known as Ppargc1β) is 
a transcriptional coactivator and is strongly induced by 
RANKL and rosiglitazone during osteoclast differentiation 
[37, 39]. Knockdown of PGC-1β in vitro inhibits osteoclast 
differentiation, and global PGC-1β deletion in mice results 
in increased bone mass due to defects in osteoclasts [40]. 
Furthermore, targeted deletion of PGC-1β in the osteoclast 
lineage resulted in complete resistance to rosiglitazone-
induced bone loss in vivo and severe attenuation of 
rosiglitazone-stimulated osteoclastogenesis ex vivo [39]. 
In accord with these studies, we suggested that the up-
regulation of PPARγ and PGC-1β in FXR−/− BMMs might 
lead to increased osteoclast formation and bone resorption in 
vitro and in vivo. We further demonstrated that the increased 
expressions of PPARγ and PGC-1β were caused by the 
reduction of JNK1/2 in FXR−/− BMMs. Indeed, a previous 
report demonstrated that PPARγ mRNA levels were increased 
in JNK1/2-deficient cells, using microarray analysis [41], 
confirming our present results. To our knowledge, the present 
study is the first to demonstrate JNK-mediated negative 
regulation of osteoclastogenesis via PPARγ and PGC-1β. 
It has been reported that IFN-β limits the excessive 
activation of osteoclast differentiation upon RANKL 
stimulation in a feedback-regulated manner [31]. In 
fact, IFN-β-knock-out mice exhibited an osteoporotic 
phenotype due to augmented osteoclastogenesis, 
indicating that IFN-β plays a critical role in the negative 
regulation of osteoclastogenesis for bone homeostasis 
[42]. Furthermore, STAT1 has been suggested as a 
mediator of IFN-β during osteoclastogenesis because 
STAT1-deficient BMMs are resistant to the suppression 
of osteoclast differentiation by IFN-β [31, 42]. In 
this study, it was demonstrated that FXR deficiency 
impaired the negative regulation of IFN-β signaling in 
osteoclastogenesis. We also found that FXR acts through 
JAK3 to modulate IFN-β signaling, since the lack of 
induction of JAK3 in FXR−/− BMMs correlated with the 
resistance to the negative regulatory effects of IFN-β on 
osteoclastogenesis. These data provide new insights into 
the role of JAK3 in RANKL-induced osteoclast formation. 
Taken together, FXR is important to maintain homeostatic 
osteoclast differentiation through negative regulation of 
the PPARγ and PGC-1β pathways and positive regulation 
of the IFN-β and STAT1 pathways. 
In addition to the role of FXR in physiological 
conditions, we also found that FXR modulates 
osteoclastogenesis and bone loss in pathological conditions 
caused by unloading or estrogen withdrawal. The world 
population is aging and the proportion of individuals over 
65 is increasing [43]. Considering that menopause occurs 
around the age of 50, millions of women will live many 
years at risk for osteoporosis and fractures. Furthermore, 
in a super-aged society, unloading-induced osteoporosis 
is also a critical issue in bedridden patients with reduced 
locomotor function. Thus, an understanding of the 
molecular mechanisms of menopause- and unloading-
induced osteoporosis is required. In this study, our data 
demonstrated that FXR has potential as a novel drug 
target for preventing postmenopausal osteoporosis and 
unloading-induced bone loss.
 In summary, we have proposed a new regulatory 
role of FXR in osteoclastogenesis (Figure 7H) in 
physiological and pathological bone loss associated with 
postmenopausal osteoporosis and disuse-induced bone 
loss. Identification and elucidation of key mediators of 
RANKL should aid in the development of therapeutic 
strategies for the treatment of such skeletal diseases.
MATERIALS AND METHODS
Reagents  
Guggulsterone, SP600125, and rosiglitazone were 
purchased from Cayman Chemical Company (Ann Arbor, 
MI, USA). Tofacitinib (JAK3 inhibitor) was purchased 
from LC Laboratories (Woburn, MA, USA). Antibodies 
against p-JNK and JNK were purchased from Cell 
Figure 5: FXR deficiency down-regulates IFN-β signaling pathways via JAK3-STAT1. (A, E) BMMs from FXR+/+ and 
FXR−/− mice were cultured with RANKL (200 ng/ml) for 24 h. The mRNA level was analyzed by real-time PCR with IFN-β or JAK3 
primer. (B) BMMs from FXR+/+ and FXR−/− mice were serum-starved for 16 h and stimulated with RANKL (200 ng/ml) for the indicated 
time. (F) BMMs from FXR+/+ and FXR−/− mice were cultured with RANKL (200 ng/ml) for the indicated time. Cell lysates were then 
subjected to western blot analysis with anti-p-STAT1 or anti-JAK3 antibody. (C, D) BMMs were infected by mock or FXR through a 
retrovirus packaging system. Infected BMMs were stimulated with RANKL (200 ng/ml) for 4 or 24 h. The mRNA levels of IFN-β and 
p-STAT1 were analyzed by real-time PCR or western blotting. (G) BMMs from FXR+/+ mice were cultured with RANKL (100 ng/ml) in the 
presence of tofacitinib, a JAK3 inhibitor, for 3 days. TRAP+ MNCs were counted as osteoclasts when more than 3 nuclei were present. Scale 
bar, 200 μm. (H) FXR+/+ BMMs were transfected with 40 nM siRNA. The siRNA-transfected FXR+/+ BMMs were cultured with RANKL 
(200 ng/ml) for 3 days, and then TRAP+ osteoclasts were counted. (I) The siRNA-transfected FXR+/+ BMMs were serum-starved for 16 h 
and stimulated with RANKL (200 ng/ml) for 4 h. (J) The siRNA-transfected FXR+/+ BMMs were cultured with RANKL (200 ng/ml) for 
24 h. Cell lysates were then subjected to western blotting analysis with anti-p-STAT1 or anti-NFATc1 antibody. Data are expressed as mean 
± SD from at least three independent experiments. Scale bar, 200 μm. *p < 0.05.
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Signaling Technology (Beverly, MA, USA). Antibodies 
against NFATc1 and JAK3 were purchased from Santa 
Cruz (Santa Cruz, CA, USA). Recombinant murine 
M-CSF and RANKL were purchased from Peprotech 
(Rocky Hill, NJ, USA). All other reagents were purchased 
from Sigma-Aldrich (St. Louis, MO, USA).
Animal model 
FXR–/– mice were generously provided by F. 
Gonzalez (NIH, Bethesda, Maryland, USA) and 
backcrossed to a C57BL/6J background for 10 
generations. Genotyping of the mice was performed 
Figure 6: FXR deficiency accelerates unloading-induced bone loss in vivo. Male 8-week-old FXR+/+ and FXR−/− mice were 
subjected to tail suspension, and mouse femurs were collected after 1 week. (A) Two-dimensional micro-CT images of the distal metaphysis 
of the femurs. (B–G) Various bone parameters of femurs were analyzed by micro-CT. BMD (g/cm3) (B), BV/TV (%) (C), Tb.Th (μm) (D), 
Tb.N (/μm) (E), Tb.Sp (μm) (F), SMI (G). (H–I) bone marrow cells (H) or BMMs (I) from FXR+/+ and FXR−/− mice were cultured with 
RANKL (100 ng/ml) and M-CSF (30 ng/ml) for 4 days and then TRAP+ osteoclasts were counted. *p < 0.05, **p < 0.01.
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Figure 7: FXR deficiency accelerates OVX-induced bone loss in vivo. Female 12-week-old mice underwent either OVX or sham 
operation, and mouse femurs were collected after 10 weeks. (A) Two-dimensional micro-CT images of the distal metaphysis of the femurs. 
(B) BMD (g/cm2) of femur from FXR+/+ and FXR−/− mice was analyzed by DXA. (C–G) Various bone parameters of femurs were analyzed 
by micro-CT. BV/TV (%) (C), Tb.Th (mm) (D), Tb.N (/mm) (E), SMI (F), Tb.Sp (mm) (G). (I) A simplified model for the role of FXR in 
osteoclastogenesis. *p < 0.05, **p < 0.01. N.S.: Not Significant.
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as previously described [22]. Mouse littermates with 
a genotype of C57BL/6J WT (FXR+/+) were used as 
controls. All mice were maintained in the animal facility 
of the Sookmyung Women’s University on a 12:12-h light-
dark cycle, and were allowed food and water ad libitum. 
All experiments were performed in accordance with the 
institutional guidelines approved by the Sookmyung 
Women’s University Animal Care and Use Committee. 
Cells and culture system
Mouse bone marrow cells were isolated from 
10–12-week-old FXR+/+ or FXR−/− C57BL/6J background 
mice. Bone marrow cells were cultured in complete 
α-MEM containing 10% (v/v) fetal bovine serum (FBS), 
supplemented with 5 ng/ml recombinant murine M-CSF 
(PeproTech) for 12 h to separate adherent and non-
adherent cells. The non-adherent cells were then harvested 
and cultured with 30 ng/ml M-CSF. After 4 days of 
culturing, the floating cells were removed and the attached 
cells were used as BMMs. All cells were cultured in 
α-MEM containing 5% (v/v) FBS at 37°C in a humidified 
atmosphere in 5% CO2 conditions.
TRAP staining of osteoclasts  
Osteoclasts were observed by staining for TRAP 
activity. Cultured cells were fixed with 10% formalin for 
10 min, permeabilized with ethanol:acetone (50:50 v/v) 
for 1 min at room temperature, and incubated in acetate 
buffer (pH 5.2) containing naphthol ASMX phosphate 
(Sigma-Aldrich) as the substrate and Fast Red Violet LB 
salt (Sigma-Aldrich) as the dye for the reaction product 
in the presence of 50 mM sodium tartrate. After washing 
with distilled water and drying, TRAP+ MNCs (n > 3) were 
counted using a light microscope. 
Quantitative real-time PCR  
Total RNA was purified with easy-BLUE (iNtRON 
Biotechnology, Seoul, Korea), and cDNA was prepared 
from 5 μg of RNA using Revert Aid™ First-Strand cDNA 
Synthesis Kit (Fermentas, Glen Burnie, MD, USA). 
Primers for osteoclastogenic genes used in this study are 
shown in Supplementary Table 1. Real-time PCR reactions 
were performed in a total volume of 20 μl, using SYBR® 
Green PCR Master Mix (Applied Biosystems, Foster 
City, CA, USA) according to the manufacturer’s protocol. 
Thermocycling was performed using a 7500 real-time 
PCR System (Applied Biosystems) with the following 
conditions: initial hold at 95°C for 10 min, followed by 40 
cycles of denaturation at 95°C for 15 s, annealing at 58°C, 
and extension at 60°C for 1 min. Data were analyzed using 
7500 System Sequence Detection Software version 2.0 
(Applied Biosystems). An index mRNA level was assessed 
using a threshold cycle (Ct) value and normalized against 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
expression.  
Immunoblot analysis  
Cells were lysed in lysis buffer (50 mM Tris HCl, pH 
7.5, 150 mM NaCl, 1% NP-40, 1 mM EDTA, 0.25% SDS, 
1 mM NaF, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl 
fluoride, pepstatin, leupeptin, and aprotinin) and were 
clarified by centrifugation. Protein was measured by 
Bradford assay (Bio-Rad Laboratories, Inc., Benicia, CA, 
USA), and equal amounts of protein were separated by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and transferred onto a polyvinylidene 
fluoride (PVDF) membrane (Immobilon-P; Millipore, 
Bedford, MA, USA). The membranes were blocked with 
5% nonfat-milk in phosphate-buffered saline with 0.1% 
Tween 20 (PBS-T) and then immunostained with the 
indicated antibodies. The membranes were developed using 
an enhanced chemiluminescence detection kit (Amersham 
Biosciences, Buckinghamshire, United Kingdom).
Bone resorption assay  
BMMs were differentiated on dentin slices with 
M-CSF and RANKL (PeproTech, Inc., Rocky Hill, 
NJ, USA) for 8 days. The cells were removed from the 
dentin slice by wiping the its surface, and then the slices 
were stained with toluidine blue (1 μg/ml; J.T. Baker, 
Philipsburg, NJ, USA). The number of pits formed by 
bone resorption on the dentin slices was counted. Image 
analysis was accomplished using ImageJ software (version 
1.32; National Institute of Health, Bethesda, MD, USA) 
according to the manufacturer’s protocol.
Retroviral gene transduction  
To generate retroviral stocks, pMX-IRES-FXR was 
transfected into the packaging cell line Platinum-E (Plat-E. 
kindly provided by Prof. S. Y. Lee at Ewha University). 
Viral supernatant was collected from culture media at 48 
h after transfection using Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA, USA) according to the manufacturer’s 
instructions. For infection with retroviruses, BMMs were 
incubated with the viral supernatant (4 ml/dish), polybrene 
(10 µg/ml, Santa Cruz, CA, USA), and M-CSF (30 ng/ml) 
for 2 days, and selected by puromycin (2 µg/ml; Sigma-
Aldrich, St. Louis, MO, USA) for an additional 48 h. 
siRNA transfection 
BMMs were seeded into 48-well plates at 
a density of 3.5 × 104 cells/well with 30 ng/ml 
M-CSF. After 24 h, cells were transfected with 40 
nM mouse JNK on-target plus smart pool siRNAs 
(5′-AAAGAATGTCCTACCTTCT-3′) (QIAGEN, 
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Hilden, Germany) or mouse JAK3 on-target plus smart 
pool siRNAs (5′-CACGTTAGACTTTGCCATCCA-3′; 
QIAGEN) using Lipofectamine 2000 (Invitrogen, Carlsbad, 
CA, USA) according to the manufacturer’s instructions. The 
control contained 40 nM non-targeting siRNA (QIAGEN). 
The transfection took place in 2.5 ml of serum-free medium 
for 6 h; the cells were then cultured for 4 days in complete 
media containing 30 ng/ml M-CSF and 100 ng/ml RANKL 
for osteoclast formation.
LPS-induced osteoclast formation in vivo  
To investigate the contribution of FXR to LPS-
induced osteoclast formation in vivo, 12-week-old FXR+/+ 
and FXR−/− male mice were directly injected with 0.5 
mg/mouse LPS on calvarial bone (n = 5 per each group). 
After 6 days, mice were euthanized. Whole calvaria 
were fixed in 4% paraformaldehyde for 24 h and then 
stained with TRAP. Image analysis was accomplished 
using ImageJ software (version 1.32; National Institute 
of Health, Bethesda, MD, USA) according to the 
manufacturer’s protocol.
Rosiglitazone-induced bone loss in vivo  
12-week-old male FXR+/+ and FXR−/− mice were 
orally administered daily either with rosiglitazone (10 
mg/kg; Cayman Chemical Company, Ann Arbor, MI, 
USA) or with control (n = 10 per each group). The 
mice were euthanized 2 months after administration. 
Femurs of mice were fixed with 70% ethanol at 4°C until 
analysis. Bone mineral density (BMD; g/cm2) of femurs 
was measured and analyzed by the dual energy X-ray 
absorptiometry (DXA) instrument PIXIMUS (GE Lunar, 
Madison, WI, USA). Three-dimensional measurements 
were performed with a micro-CT scanner and associated 
analysis software (Model 1172; Skyscan, Antwerp, 
Belgium) at 9-mm voxel size. Image acquisition was 
performed at 35 kV of energy and at an intensity of 220 
mA. The threshold was set to segment the bone from the 
background, and the same threshold setting was used for 
all samples.
Tail suspension model  
Tail suspension was conducted by applying a tape 
to the surface of the hindlimb to set a metal clip [23]. The 
other end of the clip was fixed to an overhead bar. The 
height of the bar was adjusted to maintain the mice at a 30 
degrees head-down tilt with the hindlimbs elevated above 
the floor of the cage. Male 8-week-old FXR+/+ and FXR−/− 
mice were subjected to tail suspension for 7 days. Loaded 
control mice were also housed under the same conditions 
(except for tail suspension) and for the same duration 
(n = 7 per group). 
OVX-induced bone loss in vivo  
Female 12-week-old FXR+/+ and FXR−/− mice 
underwent either ovariectomy (OVX) or sham operation 
(n = 14 per group). The mice were euthanized after 10 
weeks. Femurs of mice were fixed with 70% ethanol 
at 4°C and were analyzed by DXA and micro-CT as 
mentioned above.
Statistical analysis  
The descriptive statistics present data as the mean 
± SD. Means were compared by Student’s t-test (for 
comparison of two means) or ANOVA (for multiple 
comparisons) with a least significant difference post 
hoc test. Data represent the means and the SD from at 
least three independent experiments. Data were reported 
as statistically significant when the p-value < 0.05 for 
comparisons. Calculations were performed with the 
software package SPSS (Ver. 21.0 for windows; SPSS, 
Inc., Chicago, IL, USA).
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